Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy (Q24234853)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy (English)

0 references

main subject

anti-retroviral agent

0 references

author name string

Eliza H Humphreys

series ordinal

1

0 references

Larry W Chang

series ordinal

2

0 references

Jamal Harris

series ordinal

3

0 references

publication date

16 June 2010

0 references

published in

0 references

cites work

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Causes of the decline in AIDS deaths, United States, 1995-2002: prevention, treatment or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Estimating the mean and variance from the median, range, and the size of a sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Performance of Six Different Ritonavir-Boosted Protease Inhibitor–Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

7 January 2021

Drug resistance after failure of initial antiretroviral therapy in resource-limited countries

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

7 January 2021

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

7 January 2021

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006517.PUB3

7 January 2021